Hepatitis C Care in the Department of Veterans Affairs: Building a Foundation for Success

Infectious Disease Clinics of North America

Volumn 32, Issue 2, 2018, Pages 281-292

  Belperio, Pamela S ^a   Chartier, Maggie ^b   Gonzalez, Rachel I ^c   Park, Angela M ^b   Ross, David B ^b   Morgan, Tim R ^c   Backus, Lisa I ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Direct acting antiviral; Hepatitis C; Innovation; Population health; SVR; System redesign; Veterans

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

CLINICAL PRACTICE; ELDERLY CARE; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEPATITIS C; HUMAN; NURSE PRACTITIONER; PHARMACIST; PHYSICIAN ASSISTANT; PUBLIC HOSPITAL; REVIEW; SCREENING TEST; TELEHEALTH; TREATMENT OUTCOME; VETERAN; DISEASE MANAGEMENT; DRUG EFFECT; GOVERNMENT; HEPACIVIRUS; STATISTICS AND NUMERICAL DATA; TELEMEDICINE; UNITED STATES; VETERANS HEALTH; VIROLOGY;

ANTIVIRAL AGENTS; DISEASE MANAGEMENT; HEPACIVIRUS; HEPATITIS C; HUMANS; TELEMEDICINE; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS; VETERANS HEALTH;

EID: 85047114402     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2018.02.011     Document Type: Review

References (34)

1. Backus, L.I., Belperio, P.S., Loomis, T.P., et al. Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care. JAMA Intern Med 173 (2013), 1549–1552.
2. Dominitz, J.A., Boyko, E.J., Koepsell, T.D., et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 41 (2005), 88–96.
3. Beste, L.A., Ioannou, G.N., Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs. Epidemiol Rev 37 (2015), 131–143.
4. Denniston, M.M., Jiles, R.B., Drobeniuc, J., et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 160 (2014), 293–300.
5. Noska, A.J., Belperio, P.S., Loomis, T.P., et al. Engagement in the hepatitis C care cascade among Homeless veterans, 2015. Public Health Rep 132 (2017), 136–139.
6. US Department of Veterans Affairs, Veterans Health Administration Web site. Available at: https://www.va.gov/health/aboutVHA.asp. Accessed August 24, 2017.
7. US Department of Veterans Affairs, National Center for Veterans Analysis and Statistics, Utilization. Available at: https://www.va.gov/vetdata/Utilization.asp. Accessed August 24, 2017.
8. Brown, S.H., Lincoln, M.J., Groen, P.J., et al. VistA—US Department of Veterans Affairs national-scale HIS. Int J Med Inform 69 (2003), 135–156.
9. Perlin, J.B., Kolodner, R.M., Roswell, R.H., The Veterans Health Administration: quality, value, accountability, and information as transforming strategies for patient-centered care. Healthc Pap 5 (2005), 10–24.
10. Backus, L.I., Gavrilov, S., Loomis, T.P., et al. Clinical case registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 16 (2009), 775–783.
11. US Department of Veterans Affairs, Viral Hepatitis Web site. Available at: https://www.hepatitis.va.gov/. Accessed August 24, 2017.
12. Toussaint, J.S., Berry, L.L., The promise of Lean in health care. Mayo Clin Proc 88 (2013), 74–82.
13. Rogal, S.S., Yakovchenko, V., Waltz, T.J., et al. The association between implementation strategy use and the uptake of hepatitis C treatment in a national sample. Implement Sci 12 (2017), 60–73.
14. Backus, L.I., Belperio, P.S., Shahoumian, T.A., et al. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 39 (2014), 93–103.
15. Maier, M.M., Ross, D.B., Chartier, M., et al. Cascade of care for hepatitis C virus infection within the US Veterans Health Administration. Am J Public Health 106 (2016), 353–358.
16. Moon, A.M., Green, P.K., Berry, K., et al. Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Aliment Pharmacol Ther 45 (2017), 1201–1212.
17. Belperio, P.S., Chartier, M., Ross, D.B., et al. Curing hepatitis C virus infection: best practices from the U.S. Department of Veterans Affairs. Ann Intern Med 167:7 (2017), 499–504.
18. Backus, L.I., Belperio, P.S., Shahoumian, T.A., et al. Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients. Antivir Ther 22:6 (2017), 481–493.
19. Ioannou, G.N., Beste, L.A., Chang, M.F., et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system. Gastroenterology 151 (2016), 457–471.
20. Yehia, B.R., Schranz, A.J., Umscheid, C.A., et al. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One, 9, 2014, e101554.
21. Arora, S., Kalishman, S., Thornton, K., et al. Expanding access to hepatitis C virus treatment–Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology 52 (2010), 1124–1133.
22. Beste, L.A., Glorioso, T.J., Ho, P.M., et al. Telemedicine specialty support promotes hepatitis C treatment by primary care providers in the Department of Veterans Affairs. Am J Med 130 (2017), 432–438.
23. Ourth, H., Groppi, J., Morreale, A.P., et al. Clinical pharmacist prescribing activities in the Veterans Health Administration. Am J Health Syst Pharm 73 (2016), 1406–1415.
24. Rongey, C., Shen, H., Hamilton, N., et al. Impact of rural residence and health system structure on quality of liver care. PLoS One, 8, 2013, e84826.
25. Backus, L.I., Belperio, P.S., Shahoumian, T.A., et al. Impact of provider type on hepatitis C outcomes with boceprevir-based and telaprevir-based regimens. J Clin Gastroenterol 49 (2015), 329–335.
26. Centers for Disease Control and Prevention, Advancing team-based care through collaborative practice agreements: a resource and implementation guide for adding pharmacists to the care team. 2017, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta (GA) Available at: https://www.cdc.gov/dhdsp/pubs/docs/CPA-Team-Based-Care.pdf Accessed August 30, 2017.
27. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 47:RR-19 (1998), 1–39.
28. National Hepatitis C Program Office. Hepatitis C: military-related blood exposures, risk factors, VA care. Available at: http://www.hepatitis.va.gov/provider/policy/military-blood-exposures.asp. Accessed August 30, 2017.
29. Ross, D.B., Belperio, P.S., Chartier, M., et al. Hepatitis C testing in U.S. veterans born 1945-1965: an update. J Hepatol 66 (2017), 237–238.
30. Moyer, V.A., U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 159 (2013), 349–357.
31. Akiyama, M.J., Kaba, F., Rosner, Z., et al. Hepatitis C screening of the “birth cohort” (Born 1945-1965) and younger inmates of New York City jails. Am J Public Health 106 (2016), 1276–1277.
32. Jonas, M.C., Rodriguez, C.V., Redd, J., et al. Streamlining screening to treatment: the hepatitis C cascade of care at Kaiser Permanente mid-Atlantic states. Clin Infect Dis 62 (2016), 1290–1296.
33. Tsui, J.I., Williams, E.C., Green, P.K., et al. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend 169 (2016), 101–109.
34. Ho, S.B., Bräu, N., Cheung, R., et al. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clin Gastroenterol Hepatol 13 (2015), 2005–2014.